Bristol Myers Squibb Company $BMY Shares Acquired by Van ECK Associates Corp

Van ECK Associates Corp raised its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 7.0% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 10,553,721 shares of the biopharmaceutical company’s stock after buying an additional 693,806 shares during the period. Van ECK Associates Corp’s holdings in Bristol Myers Squibb were worth $569,268,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in BMY. Norges Bank acquired a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $1,947,272,000. Bank of New York Mellon Corp boosted its holdings in shares of Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after purchasing an additional 7,837,485 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Bristol Myers Squibb by 13.1% in the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares during the last quarter. Man Group plc boosted its holdings in Bristol Myers Squibb by 280.4% in the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock valued at $345,594,000 after acquiring an additional 5,503,391 shares during the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Bristol Myers Squibb by 530.6% in the third quarter. Two Sigma Investments LP now owns 5,453,357 shares of the biopharmaceutical company’s stock valued at $245,946,000 after acquiring an additional 4,588,601 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Trading Up 0.3%

NYSE:BMY opened at $57.05 on Friday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The firm has a market capitalization of $116.49 billion, a PE ratio of 16.02, a price-to-earnings-growth ratio of 0.16 and a beta of 0.24. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The business’s 50-day moving average is $57.73 and its two-hundred day moving average is $56.87.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The business had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period in the previous year, the company earned $1.80 earnings per share. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Research analysts predict that Bristol Myers Squibb Company will post 6.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research analyst reports. UBS Group reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Thursday, May 28th. Barclays initiated coverage on Bristol Myers Squibb in a report on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Citigroup reissued a “neutral” rating on shares of Bristol Myers Squibb in a research report on Friday, May 1st. Finally, Royal Bank Of Canada assumed coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They issued a “sector perform” rating and a $60.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $61.31.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the sale, the executive vice president directly owned 159,248 shares of the company’s stock, valued at approximately $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.05% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.